nodes	percent_of_prediction	percent_of_DWPC	metapath
Mometasone—Dermatitis acneiform—Vandetanib—thyroid cancer	0.0467	0.0505	CcSEcCtD
Mometasone—Impaired healing—Vandetanib—thyroid cancer	0.0369	0.0399	CcSEcCtD
Mometasone—Furuncle—Vandetanib—thyroid cancer	0.0325	0.0352	CcSEcCtD
Mometasone—Folliculitis—Vandetanib—thyroid cancer	0.0254	0.0275	CcSEcCtD
Mometasone—Haemoptysis—Vandetanib—thyroid cancer	0.0215	0.0233	CcSEcCtD
Mometasone—Glaucoma—Vandetanib—thyroid cancer	0.0212	0.0229	CcSEcCtD
Mometasone—Endocrine disorder—Vandetanib—thyroid cancer	0.0192	0.0208	CcSEcCtD
Mometasone—Folliculitis—Sorafenib—thyroid cancer	0.0171	0.0185	CcSEcCtD
Mometasone—Cataract—Vandetanib—thyroid cancer	0.0167	0.0181	CcSEcCtD
Mometasone—Secondary infection—Epirubicin—thyroid cancer	0.0135	0.0146	CcSEcCtD
Mometasone—Dysphonia—Sorafenib—thyroid cancer	0.0131	0.0142	CcSEcCtD
Mometasone—Gastroenteritis—Vandetanib—thyroid cancer	0.0131	0.0141	CcSEcCtD
Mometasone—Endocrine disorder—Sorafenib—thyroid cancer	0.013	0.014	CcSEcCtD
Mometasone—Secondary infection—Doxorubicin—thyroid cancer	0.0125	0.0135	CcSEcCtD
Mometasone—Sensitisation—Epirubicin—thyroid cancer	0.0111	0.0121	CcSEcCtD
Mometasone—Influenza like illness—Sorafenib—thyroid cancer	0.0104	0.0113	CcSEcCtD
Mometasone—Nasopharyngitis—Vandetanib—thyroid cancer	0.0103	0.0112	CcSEcCtD
Mometasone—Sensitisation—Doxorubicin—thyroid cancer	0.0103	0.0112	CcSEcCtD
Mometasone—Influenza—Vandetanib—thyroid cancer	0.01	0.0108	CcSEcCtD
Mometasone—Bronchospasm—Vandetanib—thyroid cancer	0.00984	0.0107	CcSEcCtD
Mometasone—Bronchitis—Vandetanib—thyroid cancer	0.00962	0.0104	CcSEcCtD
Mometasone—Leukoderma—Epirubicin—thyroid cancer	0.00935	0.0101	CcSEcCtD
Mometasone—Furunculosis—Epirubicin—thyroid cancer	0.00935	0.0101	CcSEcCtD
Mometasone—Upper respiratory tract infection—Vandetanib—thyroid cancer	0.0093	0.0101	CcSEcCtD
Mometasone—Conjunctivitis—Vandetanib—thyroid cancer	0.00867	0.00939	CcSEcCtD
Mometasone—Urinary tract infection—Vandetanib—thyroid cancer	0.00867	0.00939	CcSEcCtD
Mometasone—Leukoderma—Doxorubicin—thyroid cancer	0.00865	0.00937	CcSEcCtD
Mometasone—Furunculosis—Doxorubicin—thyroid cancer	0.00865	0.00937	CcSEcCtD
Mometasone—Epistaxis—Vandetanib—thyroid cancer	0.00841	0.00911	CcSEcCtD
Mometasone—Sinusitis—Vandetanib—thyroid cancer	0.00837	0.00906	CcSEcCtD
Mometasone—Furuncle—Epirubicin—thyroid cancer	0.0081	0.00878	CcSEcCtD
Mometasone—Furuncle—Doxorubicin—thyroid cancer	0.0075	0.00812	CcSEcCtD
Mometasone—Mediastinal disorder—Vandetanib—thyroid cancer	0.00722	0.00781	CcSEcCtD
Mometasone—Nasopharyngitis—Sorafenib—thyroid cancer	0.00698	0.00756	CcSEcCtD
Mometasone—Folliculitis—Epirubicin—thyroid cancer	0.00632	0.00685	CcSEcCtD
Mometasone—Oral candidiasis—Epirubicin—thyroid cancer	0.00626	0.00678	CcSEcCtD
Mometasone—NR3C1—Regulation of Androgen receptor activity—TRIM24—thyroid cancer	0.00613	0.0801	CbGpPWpGaD
Mometasone—Cough—Vandetanib—thyroid cancer	0.00608	0.00659	CcSEcCtD
Mometasone—Chest pain—Vandetanib—thyroid cancer	0.00593	0.00643	CcSEcCtD
Mometasone—Arthralgia—Vandetanib—thyroid cancer	0.00593	0.00643	CcSEcCtD
Mometasone—Folliculitis—Doxorubicin—thyroid cancer	0.00585	0.00634	CcSEcCtD
Mometasone—Dry mouth—Vandetanib—thyroid cancer	0.0058	0.00628	CcSEcCtD
Mometasone—Oral candidiasis—Doxorubicin—thyroid cancer	0.00579	0.00627	CcSEcCtD
Mometasone—Epistaxis—Sorafenib—thyroid cancer	0.00567	0.00614	CcSEcCtD
Mometasone—Infection—Vandetanib—thyroid cancer	0.00565	0.00612	CcSEcCtD
Mometasone—Haemoptysis—Epirubicin—thyroid cancer	0.00537	0.00581	CcSEcCtD
Mometasone—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00518	0.00561	CcSEcCtD
Mometasone—NR3C1—Nuclear Receptors—THRB—thyroid cancer	0.00515	0.0674	CbGpPWpGaD
Mometasone—NR3C1—Regulation of nuclear SMAD2/3 signaling—CITED1—thyroid cancer	0.00513	0.0671	CbGpPWpGaD
Mometasone—Paraesthesia—Vandetanib—thyroid cancer	0.00511	0.00553	CcSEcCtD
Mometasone—Otitis media—Epirubicin—thyroid cancer	0.00511	0.00553	CcSEcCtD
Mometasone—Dyspnoea—Vandetanib—thyroid cancer	0.00507	0.00549	CcSEcCtD
Mometasone—Dyspepsia—Vandetanib—thyroid cancer	0.00501	0.00542	CcSEcCtD
Mometasone—Haemoptysis—Doxorubicin—thyroid cancer	0.00497	0.00538	CcSEcCtD
Mometasone—Decreased appetite—Vandetanib—thyroid cancer	0.00494	0.00535	CcSEcCtD
Mometasone—Stinging—Epirubicin—thyroid cancer	0.00491	0.00531	CcSEcCtD
Mometasone—Fatigue—Vandetanib—thyroid cancer	0.0049	0.00531	CcSEcCtD
Mometasone—Immune system disorder—Sorafenib—thyroid cancer	0.00488	0.00528	CcSEcCtD
Mometasone—Mediastinal disorder—Sorafenib—thyroid cancer	0.00487	0.00527	CcSEcCtD
Mometasone—Pain—Vandetanib—thyroid cancer	0.00486	0.00527	CcSEcCtD
Mometasone—Dysphonia—Epirubicin—thyroid cancer	0.00483	0.00523	CcSEcCtD
Mometasone—NR3C1—FOXA2 and FOXA3 transcription factor networks—NKX2-1—thyroid cancer	0.0048	0.0628	CbGpPWpGaD
Mometasone—Otitis media—Doxorubicin—thyroid cancer	0.00472	0.00512	CcSEcCtD
Mometasone—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00465	0.00504	CcSEcCtD
Mometasone—Stinging—Doxorubicin—thyroid cancer	0.00454	0.00492	CcSEcCtD
Mometasone—Abdominal pain—Vandetanib—thyroid cancer	0.0045	0.00487	CcSEcCtD
Mometasone—Body temperature increased—Vandetanib—thyroid cancer	0.0045	0.00487	CcSEcCtD
Mometasone—Dysphonia—Doxorubicin—thyroid cancer	0.00447	0.00484	CcSEcCtD
Mometasone—Viral infection—Epirubicin—thyroid cancer	0.0044	0.00476	CcSEcCtD
Mometasone—Skin discolouration—Epirubicin—thyroid cancer	0.0044	0.00476	CcSEcCtD
Mometasone—Angioedema—Sorafenib—thyroid cancer	0.0043	0.00465	CcSEcCtD
Mometasone—Ulcer—Epirubicin—thyroid cancer	0.0042	0.00455	CcSEcCtD
Mometasone—Cough—Sorafenib—thyroid cancer	0.0041	0.00444	CcSEcCtD
Mometasone—Asthenia—Vandetanib—thyroid cancer	0.00408	0.00442	CcSEcCtD
Mometasone—Skin discolouration—Doxorubicin—thyroid cancer	0.00407	0.00441	CcSEcCtD
Mometasone—Viral infection—Doxorubicin—thyroid cancer	0.00407	0.00441	CcSEcCtD
Mometasone—NR3C1—Nuclear Receptor transcription pathway—THRB—thyroid cancer	0.00407	0.0532	CbGpPWpGaD
Mometasone—Pruritus—Vandetanib—thyroid cancer	0.00402	0.00436	CcSEcCtD
Mometasone—Musculoskeletal pain—Epirubicin—thyroid cancer	0.00402	0.00436	CcSEcCtD
Mometasone—Arthralgia—Sorafenib—thyroid cancer	0.004	0.00433	CcSEcCtD
Mometasone—Myalgia—Sorafenib—thyroid cancer	0.004	0.00433	CcSEcCtD
Mometasone—Dermatitis contact—Epirubicin—thyroid cancer	0.00393	0.00425	CcSEcCtD
Mometasone—Dry mouth—Sorafenib—thyroid cancer	0.00391	0.00424	CcSEcCtD
Mometasone—Diarrhoea—Vandetanib—thyroid cancer	0.00389	0.00421	CcSEcCtD
Mometasone—Ulcer—Doxorubicin—thyroid cancer	0.00389	0.00421	CcSEcCtD
Mometasone—Influenza like illness—Epirubicin—thyroid cancer	0.00386	0.00418	CcSEcCtD
Mometasone—Anaphylactic shock—Sorafenib—thyroid cancer	0.00384	0.00415	CcSEcCtD
Mometasone—Infection—Sorafenib—thyroid cancer	0.00381	0.00413	CcSEcCtD
Mometasone—Candida infection—Epirubicin—thyroid cancer	0.00379	0.00411	CcSEcCtD
Mometasone—Musculoskeletal pain—Doxorubicin—thyroid cancer	0.00372	0.00403	CcSEcCtD
Mometasone—Anorexia—Sorafenib—thyroid cancer	0.00366	0.00396	CcSEcCtD
Mometasone—Dermatitis contact—Doxorubicin—thyroid cancer	0.00363	0.00394	CcSEcCtD
Mometasone—Vomiting—Vandetanib—thyroid cancer	0.00362	0.00392	CcSEcCtD
Mometasone—Rash—Vandetanib—thyroid cancer	0.00359	0.00388	CcSEcCtD
Mometasone—Dermatitis—Vandetanib—thyroid cancer	0.00358	0.00388	CcSEcCtD
Mometasone—Influenza like illness—Doxorubicin—thyroid cancer	0.00357	0.00387	CcSEcCtD
Mometasone—Headache—Vandetanib—thyroid cancer	0.00356	0.00386	CcSEcCtD
Mometasone—Candida infection—Doxorubicin—thyroid cancer	0.00351	0.0038	CcSEcCtD
Mometasone—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.0035	0.00379	CcSEcCtD
Mometasone—Dyspnoea—Sorafenib—thyroid cancer	0.00342	0.0037	CcSEcCtD
Mometasone—NR3C1—Endoderm Differentiation—NKX2-1—thyroid cancer	0.00339	0.0443	CbGpPWpGaD
Mometasone—NR3C1—Transcription factor regulation in adipogenesis—RXRA—thyroid cancer	0.00339	0.0443	CbGpPWpGaD
Mometasone—Nausea—Vandetanib—thyroid cancer	0.00338	0.00366	CcSEcCtD
Mometasone—Dyspepsia—Sorafenib—thyroid cancer	0.00338	0.00366	CcSEcCtD
Mometasone—Decreased appetite—Sorafenib—thyroid cancer	0.00334	0.00361	CcSEcCtD
Mometasone—Fatigue—Sorafenib—thyroid cancer	0.00331	0.00358	CcSEcCtD
Mometasone—Pain—Sorafenib—thyroid cancer	0.00328	0.00355	CcSEcCtD
Mometasone—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00314	0.0034	CcSEcCtD
Mometasone—Body temperature increased—Sorafenib—thyroid cancer	0.00303	0.00328	CcSEcCtD
Mometasone—Abdominal pain—Sorafenib—thyroid cancer	0.00303	0.00328	CcSEcCtD
Mometasone—CYP2C8—Arachidonic acid metabolism—HPGD—thyroid cancer	0.003	0.0392	CbGpPWpGaD
Mometasone—Asthenia—Sorafenib—thyroid cancer	0.00275	0.00298	CcSEcCtD
Mometasone—Pruritus—Sorafenib—thyroid cancer	0.00271	0.00294	CcSEcCtD
Mometasone—Diarrhoea—Sorafenib—thyroid cancer	0.00263	0.00284	CcSEcCtD
Mometasone—Nasopharyngitis—Epirubicin—thyroid cancer	0.00258	0.00279	CcSEcCtD
Mometasone—Influenza—Epirubicin—thyroid cancer	0.00249	0.0027	CcSEcCtD
Mometasone—Asthma—Epirubicin—thyroid cancer	0.00249	0.0027	CcSEcCtD
Mometasone—Vomiting—Sorafenib—thyroid cancer	0.00244	0.00264	CcSEcCtD
Mometasone—Rash—Sorafenib—thyroid cancer	0.00242	0.00262	CcSEcCtD
Mometasone—Dermatitis—Sorafenib—thyroid cancer	0.00242	0.00262	CcSEcCtD
Mometasone—Headache—Sorafenib—thyroid cancer	0.0024	0.0026	CcSEcCtD
Mometasone—Bronchitis—Epirubicin—thyroid cancer	0.0024	0.0026	CcSEcCtD
Mometasone—Nasopharyngitis—Doxorubicin—thyroid cancer	0.00239	0.00258	CcSEcCtD
Mometasone—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—BRAF—thyroid cancer	0.00234	0.0306	CbGpPWpGaD
Mometasone—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.00232	0.00251	CcSEcCtD
Mometasone—Asthma—Doxorubicin—thyroid cancer	0.00231	0.0025	CcSEcCtD
Mometasone—Influenza—Doxorubicin—thyroid cancer	0.00231	0.0025	CcSEcCtD
Mometasone—Nausea—Sorafenib—thyroid cancer	0.00228	0.00247	CcSEcCtD
Mometasone—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—RXRA—thyroid cancer	0.00224	0.0292	CbGpPWpGaD
Mometasone—Bronchitis—Doxorubicin—thyroid cancer	0.00222	0.0024	CcSEcCtD
Mometasone—NR3C1—Nuclear Receptors—RXRA—thyroid cancer	0.00219	0.0286	CbGpPWpGaD
Mometasone—Urinary tract infection—Epirubicin—thyroid cancer	0.00216	0.00234	CcSEcCtD
Mometasone—Conjunctivitis—Epirubicin—thyroid cancer	0.00216	0.00234	CcSEcCtD
Mometasone—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.00214	0.00232	CcSEcCtD
Mometasone—NR3C1—Transcription factor regulation in adipogenesis—PPARG—thyroid cancer	0.00214	0.028	CbGpPWpGaD
Mometasone—Epistaxis—Epirubicin—thyroid cancer	0.0021	0.00227	CcSEcCtD
Mometasone—Sinusitis—Epirubicin—thyroid cancer	0.00209	0.00226	CcSEcCtD
Mometasone—Rhinitis—Epirubicin—thyroid cancer	0.002	0.00217	CcSEcCtD
Mometasone—Urinary tract infection—Doxorubicin—thyroid cancer	0.002	0.00217	CcSEcCtD
Mometasone—Conjunctivitis—Doxorubicin—thyroid cancer	0.002	0.00217	CcSEcCtD
Mometasone—Pharyngitis—Epirubicin—thyroid cancer	0.00198	0.00215	CcSEcCtD
Mometasone—Epistaxis—Doxorubicin—thyroid cancer	0.00194	0.0021	CcSEcCtD
Mometasone—Sinusitis—Doxorubicin—thyroid cancer	0.00193	0.00209	CcSEcCtD
Mometasone—Rhinitis—Doxorubicin—thyroid cancer	0.00185	0.002	CcSEcCtD
Mometasone—Pharyngitis—Doxorubicin—thyroid cancer	0.00183	0.00198	CcSEcCtD
Mometasone—Immune system disorder—Epirubicin—thyroid cancer	0.0018	0.00195	CcSEcCtD
Mometasone—Mediastinal disorder—Epirubicin—thyroid cancer	0.0018	0.00195	CcSEcCtD
Mometasone—NR3C1—SIDS Susceptibility Pathways—RET—thyroid cancer	0.00179	0.0234	CbGpPWpGaD
Mometasone—NR3C1—Nuclear Receptor transcription pathway—RXRA—thyroid cancer	0.00173	0.0226	CbGpPWpGaD
Mometasone—Back pain—Epirubicin—thyroid cancer	0.00168	0.00182	CcSEcCtD
Mometasone—NR3C1—Regulation of Androgen receptor activity—RXRA—thyroid cancer	0.00168	0.0219	CbGpPWpGaD
Mometasone—Immune system disorder—Doxorubicin—thyroid cancer	0.00167	0.00181	CcSEcCtD
Mometasone—Mediastinal disorder—Doxorubicin—thyroid cancer	0.00166	0.0018	CcSEcCtD
Mometasone—NR3C1—SIDS Susceptibility Pathways—THRB—thyroid cancer	0.00166	0.0218	CbGpPWpGaD
Mometasone—NR3C1—Circadian Clock—RXRA—thyroid cancer	0.00163	0.0213	CbGpPWpGaD
Mometasone—Back pain—Doxorubicin—thyroid cancer	0.00156	0.00168	CcSEcCtD
Mometasone—Cough—Epirubicin—thyroid cancer	0.00152	0.00164	CcSEcCtD
Mometasone—Myalgia—Epirubicin—thyroid cancer	0.00148	0.0016	CcSEcCtD
Mometasone—Arthralgia—Epirubicin—thyroid cancer	0.00148	0.0016	CcSEcCtD
Mometasone—Chest pain—Epirubicin—thyroid cancer	0.00148	0.0016	CcSEcCtD
Mometasone—Dry mouth—Epirubicin—thyroid cancer	0.00145	0.00157	CcSEcCtD
Mometasone—NR3C1—AP-1 transcription factor network—CDK1—thyroid cancer	0.00145	0.0189	CbGpPWpGaD
Mometasone—Anaphylactic shock—Epirubicin—thyroid cancer	0.00142	0.00154	CcSEcCtD
Mometasone—Infection—Epirubicin—thyroid cancer	0.00141	0.00153	CcSEcCtD
Mometasone—Cough—Doxorubicin—thyroid cancer	0.0014	0.00152	CcSEcCtD
Mometasone—NR3C1—Nuclear Receptors—PPARG—thyroid cancer	0.00138	0.0181	CbGpPWpGaD
Mometasone—Arthralgia—Doxorubicin—thyroid cancer	0.00137	0.00148	CcSEcCtD
Mometasone—Chest pain—Doxorubicin—thyroid cancer	0.00137	0.00148	CcSEcCtD
Mometasone—Myalgia—Doxorubicin—thyroid cancer	0.00137	0.00148	CcSEcCtD
Mometasone—CYP2C8—Metapathway biotransformation—CHST14—thyroid cancer	0.00137	0.0179	CbGpPWpGaD
Mometasone—Anorexia—Epirubicin—thyroid cancer	0.00135	0.00146	CcSEcCtD
Mometasone—Dry mouth—Doxorubicin—thyroid cancer	0.00134	0.00145	CcSEcCtD
Mometasone—Anaphylactic shock—Doxorubicin—thyroid cancer	0.00131	0.00142	CcSEcCtD
Mometasone—Infection—Doxorubicin—thyroid cancer	0.0013	0.00141	CcSEcCtD
Mometasone—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.00129	0.0014	CcSEcCtD
Mometasone—Paraesthesia—Epirubicin—thyroid cancer	0.00127	0.00138	CcSEcCtD
Mometasone—Dyspnoea—Epirubicin—thyroid cancer	0.00126	0.00137	CcSEcCtD
Mometasone—Anorexia—Doxorubicin—thyroid cancer	0.00125	0.00135	CcSEcCtD
Mometasone—Dyspepsia—Epirubicin—thyroid cancer	0.00125	0.00135	CcSEcCtD
Mometasone—Decreased appetite—Epirubicin—thyroid cancer	0.00123	0.00133	CcSEcCtD
Mometasone—Fatigue—Epirubicin—thyroid cancer	0.00122	0.00132	CcSEcCtD
Mometasone—Pain—Epirubicin—thyroid cancer	0.00121	0.00131	CcSEcCtD
Mometasone—NR3C1—Circadian Clock—HIF1A—thyroid cancer	0.00121	0.0158	CbGpPWpGaD
Mometasone—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.0012	0.00129	CcSEcCtD
Mometasone—Paraesthesia—Doxorubicin—thyroid cancer	0.00118	0.00128	CcSEcCtD
Mometasone—Dyspnoea—Doxorubicin—thyroid cancer	0.00117	0.00127	CcSEcCtD
Mometasone—Gastrointestinal pain—Epirubicin—thyroid cancer	0.00116	0.00126	CcSEcCtD
Mometasone—Dyspepsia—Doxorubicin—thyroid cancer	0.00116	0.00125	CcSEcCtD
Mometasone—Decreased appetite—Doxorubicin—thyroid cancer	0.00114	0.00124	CcSEcCtD
Mometasone—Fatigue—Doxorubicin—thyroid cancer	0.00113	0.00122	CcSEcCtD
Mometasone—Pain—Doxorubicin—thyroid cancer	0.00112	0.00121	CcSEcCtD
Mometasone—Body temperature increased—Epirubicin—thyroid cancer	0.00112	0.00121	CcSEcCtD
Mometasone—Abdominal pain—Epirubicin—thyroid cancer	0.00112	0.00121	CcSEcCtD
Mometasone—NR3C1—SIDS Susceptibility Pathways—PRKAR1A—thyroid cancer	0.00111	0.0145	CbGpPWpGaD
Mometasone—NR3C1—Nuclear Receptor transcription pathway—PPARG—thyroid cancer	0.00109	0.0143	CbGpPWpGaD
Mometasone—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.00107	0.00116	CcSEcCtD
Mometasone—Abdominal pain—Doxorubicin—thyroid cancer	0.00104	0.00112	CcSEcCtD
Mometasone—Body temperature increased—Doxorubicin—thyroid cancer	0.00104	0.00112	CcSEcCtD
Mometasone—Asthenia—Epirubicin—thyroid cancer	0.00102	0.0011	CcSEcCtD
Mometasone—Pruritus—Epirubicin—thyroid cancer	0.001	0.00109	CcSEcCtD
Mometasone—NR3C1—AP-1 transcription factor network—HIF1A—thyroid cancer	0.000997	0.013	CbGpPWpGaD
Mometasone—NR3C1—Generic Transcription Pathway—TRIM33—thyroid cancer	0.000973	0.0127	CbGpPWpGaD
Mometasone—Diarrhoea—Epirubicin—thyroid cancer	0.00097	0.00105	CcSEcCtD
Mometasone—Asthenia—Doxorubicin—thyroid cancer	0.000941	0.00102	CcSEcCtD
Mometasone—CYP2C8—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000936	0.0122	CbGpPWpGaD
Mometasone—Pruritus—Doxorubicin—thyroid cancer	0.000928	0.00101	CcSEcCtD
Mometasone—Vomiting—Epirubicin—thyroid cancer	0.000902	0.000976	CcSEcCtD
Mometasone—Diarrhoea—Doxorubicin—thyroid cancer	0.000898	0.000972	CcSEcCtD
Mometasone—Rash—Epirubicin—thyroid cancer	0.000894	0.000968	CcSEcCtD
Mometasone—Dermatitis—Epirubicin—thyroid cancer	0.000893	0.000967	CcSEcCtD
Mometasone—Headache—Epirubicin—thyroid cancer	0.000888	0.000962	CcSEcCtD
Mometasone—NR3C1—SIDS Susceptibility Pathways—SST—thyroid cancer	0.000874	0.0114	CbGpPWpGaD
Mometasone—Nausea—Epirubicin—thyroid cancer	0.000842	0.000912	CcSEcCtD
Mometasone—Vomiting—Doxorubicin—thyroid cancer	0.000834	0.000903	CcSEcCtD
Mometasone—Rash—Doxorubicin—thyroid cancer	0.000827	0.000896	CcSEcCtD
Mometasone—Dermatitis—Doxorubicin—thyroid cancer	0.000827	0.000895	CcSEcCtD
Mometasone—Headache—Doxorubicin—thyroid cancer	0.000822	0.00089	CcSEcCtD
Mometasone—NR3C1—Adipogenesis—RXRA—thyroid cancer	0.000818	0.0107	CbGpPWpGaD
Mometasone—Nausea—Doxorubicin—thyroid cancer	0.000779	0.000844	CcSEcCtD
Mometasone—CYP2C8—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000759	0.00993	CbGpPWpGaD
Mometasone—NR3C1—Generic Transcription Pathway—THRB—thyroid cancer	0.000703	0.0092	CbGpPWpGaD
Mometasone—NR3C1—Adipogenesis—HIF1A—thyroid cancer	0.000608	0.00795	CbGpPWpGaD
Mometasone—NR3C1—AP-1 transcription factor network—CCND1—thyroid cancer	0.000602	0.00788	CbGpPWpGaD
Mometasone—NR3C1—AP-1 transcription factor network—PTEN—thyroid cancer	0.000581	0.00761	CbGpPWpGaD
Mometasone—CYP2C8—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000538	0.00704	CbGpPWpGaD
Mometasone—NR3C1—SIDS Susceptibility Pathways—HIF1A—thyroid cancer	0.000525	0.00687	CbGpPWpGaD
Mometasone—NR3C1—Adipogenesis—PPARG—thyroid cancer	0.000517	0.00676	CbGpPWpGaD
Mometasone—NR3C1—FOXA2 and FOXA3 transcription factor networks—AKT1—thyroid cancer	0.000486	0.00635	CbGpPWpGaD
Mometasone—NR3C1—Gene Expression—TRIM33—thyroid cancer	0.000468	0.00612	CbGpPWpGaD
Mometasone—NR3C1—Generic Transcription Pathway—MEN1—thyroid cancer	0.000447	0.00584	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000429	0.00561	CbGpPWpGaD
Mometasone—CYP2C8—Biological oxidations—RXRA—thyroid cancer	0.000403	0.00527	CbGpPWpGaD
Mometasone—NR3C1—AP-1 transcription factor network—TP53—thyroid cancer	0.000397	0.00519	CbGpPWpGaD
Mometasone—NR3C1—Glucocorticoid receptor regulatory network—TP53—thyroid cancer	0.00035	0.00457	CbGpPWpGaD
Mometasone—NR3C1—Gene Expression—THRB—thyroid cancer	0.000339	0.00443	CbGpPWpGaD
Mometasone—NR3C1—Generic Transcription Pathway—RXRA—thyroid cancer	0.000299	0.00391	CbGpPWpGaD
Mometasone—NR3C1—Regulation of nuclear SMAD2/3 signaling—AKT1—thyroid cancer	0.000298	0.0039	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—MINPP1—thyroid cancer	0.000296	0.00387	CbGpPWpGaD
Mometasone—NR3C1—Glucocorticoid receptor regulatory network—AKT1—thyroid cancer	0.000295	0.00386	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—NDUFA13—thyroid cancer	0.000252	0.00329	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—CHST14—thyroid cancer	0.000237	0.0031	CbGpPWpGaD
Mometasone—NR3C1—Gene Expression—TPR—thyroid cancer	0.000229	0.00299	CbGpPWpGaD
Mometasone—NR3C1—Gene Expression—MEN1—thyroid cancer	0.000215	0.00281	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—HPGD—thyroid cancer	0.000191	0.0025	CbGpPWpGaD
Mometasone—NR3C1—Generic Transcription Pathway—PPARG—thyroid cancer	0.000189	0.00247	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000155	0.00203	CbGpPWpGaD
Mometasone—NR3C1—Gene Expression—RXRA—thyroid cancer	0.000144	0.00188	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—TPR—thyroid cancer	0.00011	0.00143	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—PRKAR1A—thyroid cancer	0.000108	0.00141	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	9.78e-05	0.00128	CbGpPWpGaD
Mometasone—NR3C1—Gene Expression—PPARG—thyroid cancer	9.08e-05	0.00119	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—SLC5A5—thyroid cancer	8.21e-05	0.00107	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	7.69e-05	0.00101	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—RXRA—thyroid cancer	6.9e-05	0.000902	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	6.71e-05	0.000877	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—PPARG—thyroid cancer	4.35e-05	0.000569	CbGpPWpGaD
Mometasone—NR3C1—Gene Expression—AKT1—thyroid cancer	3.59e-05	0.00047	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—PTGS2—thyroid cancer	3.43e-05	0.000448	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—PTEN—thyroid cancer	2.99e-05	0.000391	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—AKT1—thyroid cancer	1.72e-05	0.000225	CbGpPWpGaD
